Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2+ metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA. 31/GSK EGF 108 919. 2012 ASCO Annual Meeting. Oral Abstract Session, Breast Cancer – HER2/ER. Abstract No: LBA671 - Gelmon, K A; Boyle, F; Kaufman, B
et al.